Drug intelligence / Profile preview

TEDDI

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

TEDDI is a chemotherapy platform comprising temozolomide, etoposide, doxil (liposomal doxorubicin), dexamethasone, and ibrutinib. This combination regimen is being investigated for the treatment of aggressive B-cell lymphomas, particularly those involving the central nervous system. Temozolomide is an alkylating agent, etoposide is a topoisomerase inhibitor, doxil is an anthracycline topoisomerase inhibitor, dexamethasone is a corticosteroid, and ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. The regimen aims to improve outcomes in conditions like primary CNS lymphoma and secondary CNS lymphoma.

Targets

GR (Glucocorticoid receptor)BTK (Bruton tyrosine kinase)TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on TEDDI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEDDI.

Explore the full profile